Demant’s half-year financials have fuelled “high expectations” from the Danish group ahead of roll-out of its new flagship hearing aid family , Oticon Reveal. The group reported 7% organic growth in the first half of 2026, ahead of expectations , as momentum strengthened across all three business areas and the hearing healthcare group gained market share....
Continue reading at Audiology Worldnews
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change — this is a financial performance report; clinicians should monitor for Oticon Reveal product availability and specifications when the device launches.
Strong organic growth at a market leader signals continued R&D investment and competitive pricing pressure across the hearing aid industry.
- 01Demant posted 7% organic growth in H1 2026, beating analyst expectations.
- 02The company upgraded its full-year 2026 financial outlook on the back of these results.
- 03A new flagship hearing aid family, Oticon Reveal, is planned for imminent launch.
- 04Positive financials suggest sustained manufacturing and distribution capacity for clinics.
- 05No clinical data on Oticon Reveal were disclosed in this report.
Demant achieved 7% organic growth in H1 2026.
press releasesupportedDemant upgraded its full-year 2026 financial outlook.
press releasesupportedOticon Reveal is a new flagship hearing aid family planned for launch.
press releaseunclear
